MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer-Reference-Cited by-同舟云学术

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Published:2020-02-21 Issue:11 Volume:26 Page:2535-2545
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Dagogo-Jack Ibiayi,Yoda Satoshi^ORCID,Lennerz Jochen K.^ORCID,Langenbucher Adam,Lin Jessica J.^ORCID,Rooney Marguerite M.,Prutisto-Chang Kylie,Oh Audris,Adams Nathaniel A.,Yeap Beow Y.,Chin Emily,Do Andrew^ORCID,Marble Hetal D.,Stevens Sara E.,Digumarthy Subba R.^ORCID,Saxena Ashish,Nagy Rebecca J.,Benes Cyril H.^ORCID,Azzoli Christopher G.,Lawrence Michael S.,Gainor Justin F.,Shaw Alice T.,Hata Aaron N.

Funder

Conquer Cancer

Amgen Young Investigator Award

American Cancer Society

NCI Career Development Award

Lung Cancer Research Foundation

AstraZeneca Young Investigator Award

NCI

Cure for Lung Cancer Research Fund

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance;JTO Clinical and Research Reports;2024-09

2. AXL and SHC1 confer crizotinib resistance in patient-derived xenograft model of ALK-driven lung cancer;iScience;2024-09

3. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

4. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

5. Lung cancer associated with an activating mutation in the 14th exon of the MET gene;Meditsinskiy sovet = Medical Council;2024-07-25